ProMetic Life Sciences Inc. (PLI) 2015年年度报告「TSX」.pdf

1、1THE BIOLOGY OF HEALINGWe are the company that can effectively address the entire healing process in a groundbreaking way using both small molecule drugs and plasma protein therapies.We are continuously discovering new innovations to regulate the cycle of healing.We do it,not because we have to,but

2、because we are compelled to.Its at the heart of our culture to provide a pathway to hope.22015 has been a year of industrious operational and product development execution.I am very happy and proud to report that ProMetic delivered,as anticipated,on the majority of its ambitious corporate,operationa

3、l and clinical objectives set for the year.Many years of hard work and significant financial investment have been expended to build and develop world-class proprietary manufacturing and product development platforms.ProMetic has reached the stage where all the necessary components combine to create

4、a fully integrated biopharmaceutical company possessing a rich pipeline of innovative plasma-derived and small molecule therapeutics,targeting a multitude of unmet medical needs.During 2015,ProMetic was very active in pursuing one of the key steps in the drug development process,transitioning from p

5、reclinical to clinical studies.This followed the successful filing and clearance of investigational new drug applications by the relevant regulatory authorities for both plasma-derived and small molecule drugs.This particular step,which marks the beginning of testing in human patients to generate pr

6、oof of concept efficacy data,is a recognized milestone and value creation event in our industry.As expected,the market rewarded ProMetics performance accordingly.Several important milestones were achieved across our small-molecule program:The approval for our orally active,anti-fibrotic,lead drug ca